Lawlor, R.T.; Mattiolo, P.; Mafficini, A.; Hong, S.-M.; Piredda, M.L.; Taormina, S.V.; Malleo, G.; Marchegiani, G.; Pea, A.; Salvia, R.;
et al. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers 2021, 13, 3119.
https://doi.org/10.3390/cancers13133119
AMA Style
Lawlor RT, Mattiolo P, Mafficini A, Hong S-M, Piredda ML, Taormina SV, Malleo G, Marchegiani G, Pea A, Salvia R,
et al. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers. 2021; 13(13):3119.
https://doi.org/10.3390/cancers13133119
Chicago/Turabian Style
Lawlor, Rita T., Paola Mattiolo, Andrea Mafficini, Seung-Mo Hong, Maria L. Piredda, Sergio V. Taormina, Giuseppe Malleo, Giovanni Marchegiani, Antonio Pea, Roberto Salvia,
and et al. 2021. "Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions" Cancers 13, no. 13: 3119.
https://doi.org/10.3390/cancers13133119
APA Style
Lawlor, R. T., Mattiolo, P., Mafficini, A., Hong, S.-M., Piredda, M. L., Taormina, S. V., Malleo, G., Marchegiani, G., Pea, A., Salvia, R., Kryklyva, V., Shin, J. I., Brosens, L. A., Milella, M., Scarpa, A., & Luchini, C.
(2021). Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers, 13(13), 3119.
https://doi.org/10.3390/cancers13133119